Osiris Sells Osteocel: Up To $137M For Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Money to push two Phase III products in the bank by the end of 2009, CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Osiris/Genzyme Put Stem Cells On The Deal Map
First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.
Osiris/Genzyme Put Stem Cells On The Deal Map
First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.
Osiris Stem Cell Knee Therapy Misses Endpoint
Further evidence of improvement in ongoing Phase I/II trial could lead firm to focus on osteoarthritis of the knee.